Sarepta halts three studies testing gene therapy for muscle disorder-March 2024-www.financetom.com

Sarepta halts three studies testing gene therapy for muscle disorder

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Sarepta halts three studies testing gene therapy for muscle disorder

Apr 4, 2025 6:16 AM

April 4 (Reuters) - Sarepta Therapeutics ( SRPT ) said

on Friday it would temporarily halt three trials testing its

gene therapy Elevidys.

Last month, the company said a 16-year-old boy died from

acute liver failure months after receiving the gene therapy for

a rare muscular dystrophy.

Previous page： Neogen Q4 revenue misses analyst expectations Next page： Energous Q2 revenue hits $1 mln, net loss improves 35%

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Neogen Q4 revenue misses analyst expectations

Jul 29, 2025

Overview * Neogen Q4 revenue falls 4.8% yr/yr to $225.5 mln, impacted by market conditions * Net loss of $612.2 mln due to non-cash goodwill impairment from 3M acquisition * Adjusted EPS of $0.05 misses analyst expectations, per LSEG data Outlook * Neogen sees fiscal 2026 revenue between $820 mln and $840 mln * Company expects fiscal 2026 adjusted EBITDA...

Energous Q2 revenue hits $1 mln, net loss improves 35%

Jul 29, 2025

Overview * Energous ( WATT ) Q2 revenue reaches $1 mln, highest since 2016, up 184% qtr/qtr * Net loss improves 35% yr/yr, lowest quarterly loss in a decade * Co announces $4 mln order backlog, indicating growing demand Outlook * Company expects $4 mln order backlog to ship in 2025 Result Drivers * REVENUE GROWTH - Co attributes 184%...

GeneDx Swings to Q2 Adjusted Earnings as Revenue Increases; Fiscal 2025 Revenue Outlook Raised

Jul 29, 2025

07:11 AM EDT, 07/29/2025 (MT Newswires) -- GeneDx Holdings ( WGS ) reported Q2 adjusted earnings Tuesday of $0.50 per diluted share, swinging from an adjusted loss of $0.08 per share a year earlier. Analysts polled by FactSet expected $0.12. Revenue for the quarter ended June 30 was $102.7 million, up from $68.9 million a year earlier. Analysts surveyed by...

Google agrees $36 million fine for anti-competitive deals with Australia telcos

Aug 17, 2025

SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...